التخطي إلى المحتوى

America has a brand new weapon within the struggle in opposition to weight problems. The FDA on Friday approved a brand new weight-loss drug, Wegovy, for people who find themselves both overweight or obese and have at the very least one weight-related medical downside. 

“We’ve to consider weight problems no totally different than hypertension, than excessive ldl cholesterol, than diabetes,” mentioned Dr. Domenica Rubino, the director of the Washington Heart for Weight Administration and Analysis. 

Rubino mentioned individuals taking current weight problems drugs lose a median of about 7% to 9% of their physique weight. “Individuals who require 10%, 15%, 20% weight reduction, we’d like instruments,” she mentioned.

Throughout a 16-month research, sufferers on Wegovy misplaced a median of 17% of their physique weight. Unwanted effects included diarrhea and nausea, which normally resolved because the dose was slowly elevated. Sufferers taken off the drug gained again greater than half their weight reduction. 

Trial participant Lisa Robillard misplaced 63 kilos. She mentioned she beforehand tried fad diets or some other strategies she thought would assist her drop some pounds. 

“I wasn’t hungry between meals, which was simply unparalleled for me. I used to be fuller faster and cravings that I had disappeared,” she mentioned of the brand new drug. 

supply : information.google.com

قد يهمك أيضاً :-

  1. I'm Fat And Diabetic. Here's Why Your 'Concern' For My Health Is Destructive.
  2. Novo Nordisk, armed with Wegovy inexperienced mild, preps aggressive push to construct weight problems market
  3. FDA approves groundbreaking drug to battle weight problems
  4. Pandemic reveals threat of weight problems, and problem of weight reduction
  5. FDA approves new drug to struggle weight problems
  6. FDA approves new drug to battle weight problems
  7. Weight problems drug authorized by FDA, giving 'improbable outcomes' regionally

التعليقات

اترك تعليقاً

لن يتم نشر عنوان بريدك الإلكتروني. الحقول الإلزامية مشار إليها بـ *